Merck's Keytruda, ready to challenge Bristol-Myers Squibb, posts kidney cancer combination win

Merck’s Keytruda knows how to make an entrance. On Thursday, it hit the scene with kidney cancer combination data that could snag it a new indication months earlier than anticipated.